Bibliographic information

GuidelineWHO consolidated guidelines on tuberculosis: module 4: treatment and care
Year of Publication2025
Issuing InstitutionWorld Health Organization

Recommendation

Maintained

Surgery for patients on MDR/RR-TB treatment: In patients with rifampicin-resistant tuberculosis (RR-TB) or multidrug-resistant TB (MDR-TB), elective partial lung resection (lobectomy or wedge resection) may be used alongside a recommended MDR-TB regimen.

Recommended in favor

Conditional

Notes and Remarks

Subgroup considerations The relative benefits of surgery are expected to depend substantially on the population subgroups that are targeted. The analysis could not provide a refined differentiation of the type of patient who would be best suited to benefit from the intervention or the type of intervention that would have the most benefit. The effect is expected to be moderate in the average patient considered appropriate for surgery. The odds of success for patients with XDR-TB (pre-2021 definition) were statistically significantly lower when they underwent surgery compared with other patients (aOR: 0.4, 95% CL:

  • 0.2–0.9). This effect is likely to be biased, given that patients who underwent surgery would have had other factors predisposing to poor outcomes that could not be adjusted for. Implementation considerations Partial lung resection for patients with MDR-TB is to be considered only under conditions of good surgical facilities and trained and experienced surgeons, and with careful selection of candidates.

Also Featured In

This recommendation also appears in the following guidelines:

Originally Developed
Guideline

WHO Treatment Guidelines for Drug-Resistant Tuberculosis, 2016 Update

Year2016
Institution
Guideline

WHO guidelines on tuberculosis infection prevention and control: 2019 update

Year2019
InstitutionWHO
Guideline

WHO consolidated guidelines on drug-resistant tuberculosis treatment

Year2019
InstitutionWorld Health Organization
Guideline

WHO consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-resistant tuberculosis treatment

Year2020
InstitutionWorld Health Organization
Guideline

WHO consolidated guidelines on tuberculosis: Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update

Year2022
InstitutionWorld Health Organization